Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review - PubMed (original) (raw)
Review
. 2012 Jun;34(6):1247-1258.e22.
doi: 10.1016/j.clinthera.2012.04.013. Epub 2012 May 18.
Affiliations
- PMID: 22608780
- DOI: 10.1016/j.clinthera.2012.04.013
Free article
Review
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review
Vanita R Aroda et al. Clin Ther. 2012 Jun.
Free article
Erratum in
- Clin Ther. 2014 Feb 1;36(2):307-8
Abstract
Background: Considerable clinical data on the treatment of type 2 diabetes with incretin-based therapies (glucagon-like peptide 1 receptor agonists [GLP-1RAs] and dipeptidyl-peptidase IV [DPP-4] inhibitors) are available.
Objective: This meta-analysis was performed to support the understanding of the overall evidence by summarizing the findings from studies of the incretin-based therapies.
Methods: The MEDLINE, EMBASE, BIOSIS, and BIOSIS trial databases were searched for relevant literature published between January 1, 1990, and June 30, 2011. Search terms included GLP-1, DPP-4, the names of drugs that have been approved by the US Food and Drug Administration for the treatment of diabetes, and the names of drugs that have not been approved but are in late-stage research. Studies were included if they were randomized controlled trials of 12 to 52 weeks' duration and having change from baseline in hemoglobin (Hb) A(1c) as the primary end point. The random effects meta-analyses models examined HbA(1c), fasting plasma glucose (FPG), and body weight for individual therapies, but did not compare effects between therapies.
Results: The reviewers identified 362 unique clinical studies, of which 80 were eligible for inclusion in the present meta-analysis. Mean baseline HbA(1c) values ranged from 7.4% to 10.3% (GLP-1RA studies) and 7.2% to 9.3% (DPP-4 inhibitor studies). The highest maintenance doses of the GLP-1RAs and the DPP-4 inhibitors were associated with changes from baseline in mean HbA(1c) of -1.1% to -1.6% and -0.6% to -1.1%, respectively. Mean reductions in FPG with exenatide once weekly (QW) or liraglutide once daily were apparently greater than those with exenatide twice daily (BID) and the DPP-4 inhibitors, with the exception of vildagliptin. Mean weight losses with the GLP-1RAs and the DPP-4 inhibitors were >-2.0 and -0.2 to -0.6 kg, respectively. The limitations of the present analysis included a lack of adjustment for placebo use and interstudy heterogeneity associated with differences in methodology (eg, management of concurrent medications, blinding, criteria for treatment discontinuation).
Conclusions: All of the incretin-based therapies in the present meta-analysis were associated with significant reductions from baseline in HbA(1c) and FPG. Further direct comparative studies between the GLP-1RAs and the DPP-4 inhibitors and within the GLP-1RA class are justified.
Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.
Similar articles
- Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S. Cornell S. J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. J Clin Pharm Ther. 2012. PMID: 22436069 Review. - Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF, Mannucci E, Ahrén B. Deacon CF, et al. Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Diabetes Obes Metab. 2012. PMID: 22471248 Review. - Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X, Divino V, Amamoo J, Xie L, Coyle KB, Gamble CL, Guevarra M, Paprocki Y, King AA. Tan X, et al. Clin Drug Investig. 2024 Apr;44(4):271-284. doi: 10.1007/s40261-024-01354-2. Epub 2024 Mar 20. Clin Drug Investig. 2024. PMID: 38507188 Free PMC article. - Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Karagiannis T, et al. BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369. BMJ. 2012. PMID: 22411919
Cited by
- Machine learning assessment of vildagliptin and linagliptin effectiveness in type 2 diabetes: Predictors of glycemic control.
Esaifan HA, Saadah LM, Abu Hammour K, Abu Farha RK. Esaifan HA, et al. PLoS One. 2024 Aug 26;19(8):e0309365. doi: 10.1371/journal.pone.0309365. eCollection 2024. PLoS One. 2024. PMID: 39186745 Free PMC article. - Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis.
Saadi MSS, Das R, Mullath Ullas A, Powell DE, Wilson E, Myrtziou I, Rakieh C, Kanakis I. Saadi MSS, et al. Int J Mol Sci. 2024 Jul 22;25(14):7988. doi: 10.3390/ijms25147988. Int J Mol Sci. 2024. PMID: 39063229 Free PMC article. Review. - Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition.
Xie Y, Zhou Q, He Q, Wang X, Wang J. Xie Y, et al. Acta Pharm Sin B. 2023 Jun;13(6):2383-2402. doi: 10.1016/j.apsb.2022.11.008. Epub 2022 Nov 11. Acta Pharm Sin B. 2023. PMID: 37425060 Free PMC article. Review. - Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.
Zhang J, Xian TZ, Teng Y, Wang X, Wu MX, Li C, Wang W, Man F, Zhang X, Wang X, Guo LX. Zhang J, et al. Int J Clin Pract. 2022 Oct 10;2022:7128859. doi: 10.1155/2022/7128859. eCollection 2022. Int J Clin Pract. 2022. PMID: 37214201 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous